Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: CNS tumours

282MO - Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients


10 Sep 2022


Mini Oral session: CNS tumours


Supportive Care and Symptom Management;  Radiation Oncology

Tumour Site

Central Nervous System Malignancies


Olav Yri


Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047


O.E. Yri1, G.L. Astrup1, A.T. Karlsson1, Ø. Paulsen2, R. Van Helvoirt3, J. Lund4, M. Taran5, M. Jensen Hjermstad1, M. Birketvedt1, E. Bjerkeset1, N. Aass1, S. Kaasa1

Author affiliations

  • 1 Oncology Dept/european Palliative Care Research Centre (prc), Oslo University Hospital, 0424 - Oslo/NO
  • 2 Heamatology And Oncology, Sykehuset Telemark HF, Skien/NO
  • 3 Oncology, Sorlandet Hospital, 4615 - Kristiansand/NO
  • 4 Oncology, Helse More og Romsdal HF, 6026 - Alesund/NO
  • 5 Oncology, Sykehuset i Vestfold HF, 3103 - Tonsberg/NO


Login to access the resources on OncologyPRO.

Abstract 282MO


Radiotherapy (RT) is frequently used in brain metastases (BM) treatment. RCTs show equal survival after stereotactic RT (SRT) and whole-brain RT (WBRT) in patients with favorable prognostic factors (i.e. ≤4 BM, good performance status [PS]), while WBRT may not improve survival in patients with more advanced cancer. We investigated what type of anticancer treatments pts were offered at the time of primary BM diagnosis. Patients were grouped according to anticancer treatments and known prognostic criteria. Survival and patient-reported outcomes (PROs) were compared between groups in this “real-life cohort” of consecutive, unselected BM pts.


A population-based prospective observational study at 5 hospitals in Norway (covering ≈70% of the Norwegian population). Clinical data were collected every 3 months, PROs monthly for 1 year.


914 patients were included (46 % male, median age 69 [21-96]). Most frequent primary cancers were lung (non-small cell, 41%), melanoma (16%), breast (14%) and colorectal (10%). 31% had ≥5 BM, 82% were symptomatic, 41% had ECOG PS ≥2, 80% had extracranial metastases (ECM). Primary BM treatments were: Surgery 17%; SRT 34%; WBRT 40%, systemic treatments 3%; best supportive care (BSC) 6%. Median OS (mOS) after BM diagnosis for all was 6 months (surgery: 13, SRT: 9, systemic: 8, WBRT: 3, BSC: 1). In patients treated with WBRT, 71% had ≥5 BM, 50% ECOG 2-4, 87% ECM, 50% were ≥70 years. mOS for WBRT patients with ECOG 0, 1, 2 and 3-4 was 9, 4, 2 and 2 months, respectively. At inclusion, patients in the WBRT group reported significantly poorer scores for physical functioning (PF) and global quality of life (QoL) compared to those in the surgery and SRT groups. After 2 months, PF, QoL and fatigue scores significantly worsened in the WBRT group, with no change after surgery or SRT.


Clinical data (ECOG, ECM status) and PROs indicate a need for more careful selection of patients offered WBRT. Due to particularly short survival, patients with ECOG 3-4, and perhaps controversially also ECOG 2, may not be able to profit from WBRT. These patients should instead be considered for BSC alone.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.


The Norwegian Cancer Society. South-East Health Care Region of Norway.


O.E. Yri: Non-Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.